The company's corporate governance is based on the best world practices and the principles of professionalism, ethics and objectivity. Independent directors provide independent judgment and strategic vision. A detailed understanding of the market and the company’s potential is the contribution of experienced top managers.
Strategy formation
Strategy formation
Board of Directors
Marina Penkova Marina Penkova
Marina Penkova
Member of the Board of Directors
Implementation of the strategy
Implementation of the strategy
Corporate management
Alexander Efremov Alexander Efremov
Alexander Efremov
General Director

Alexander Efremov graduated from the Military Medical Academy, then postgraduate studies at the Department of Naval and General Therapy. He also graduated from Russian Academy of Public Administration (now RANEPA) in the specialty of State and Municipal Administration. Passed management retraining courses at Harvard University, IMD School and Stanford University.

He has been working in the field of healthcare for more than thirty years: started as a military doctor in the naval personnel of the Northern Fleet of the Armed Forces of the Russian Federation, worked as an adjunct at the Department of Therapy at the Medical Academy, where he defended his PhD thesis in Cardiology, invasive methods of treatment of cardiac arrhythmias. Alexander Efremov worked as a senior resident of the clinic, taught at the department, continued research, helping applicants in the preparation of scientific papers.

Then he joined the pharmaceutical field, where he worked his way up to the General Manager of the representative office, led a number of large foreign pharmaceutical and medical device companies in Russia and the CIS.

In 2022, he joined the Promomed team. In the position of Executive Director he is responsible for shaping the Company's strategy in the commercial segment of the pharmaceutical market, selecting an active product portfolio, launching new products to the markets of Russia and the CIS, operational marketing and promotion of the Company's commercial portfolio.

Alexander Efremov is the author of scientific papers published in Russia and abroad, speaker at industry events, a member of the Strategy Council of one of the Eastern European companies.

Ilya Bardin-Denisov Ilya Bardin-Denisov
Ilya Bardin-Denisov
Director of Operations
Yuriy Troyankin Yuriy Troyankin
Yuriy Troyankin
Director, Human Resources and Organizational Development

Yuri Troyankin graduated from Moscow Institute of Physics and Technology (State University).

He completed professional retraining at the Plekhanov Russian Academy of Economics and Thunderbird American Graduate School of International Management.

He has been working in the field of human resource management for more than 20 years, having worked his way up from a specialist to a top manager in holding-type organizations, industry leaders, including banking/financial institutions, oil industry, mechanical engineering, metallurgy, housing and communal services, construction and real estate, agribusiness, consumer goods industry, and pharmaceutical industry. Yuri Troyankin has a successful experience in building an organization, forming teams and talent management, transforming corporate culture, strategic development and change management. 

He joined the Promomed team at the end of 2020. His area of responsibility includes human capital management, organizational development, and transformational processes.

Kira Zaslavskaya Kira Zaslavskaya
Kira Zaslavskaya
Director, New Products

Kira Zaslavskaya has more than 10 years of experience in the medical sector. She started her career as a medical representative and now she is a top manager at a major pharmaceutical company.

In 2009, she joined the team of Promomed Group. As Director for New Products, she is responsible for the product portfolio development strategy, the introduction of new technologies in the development of medicines, the organization of preclinical and clinical trials and the launch of products on the market.

Kira Zaslavskaya participated in the implementation of the world’s largest observational post-marketing study in endocrinlogy of the efficacy and safety of Reduxin®, as well as in the development, study and market launch of Areplivir®, the drug for coronavirus infection.

She graduated from the Mendeleev Russian University of Chemical Technology and passed postgraduate training program at the Nesmeyanov Institute of Organoelement Compounds of the Russian Academy of Sciences.  She is an author of numerous scientific papers, a competent speaker at industry events
Timofey Soloviev Timofey Soloviev
Timofey Soloviev
Director, Economics and Finance